Aegle Therapeutics Corp. is a clinical-stage biotechnology company developing novel extracellular vesicle (“EV”) therapies to address rare and serious diseases and disorders with significant unmet medical needs. Aegle’s proprietary platform technology safely isolates native extracellular vesicles (“EVs”) from stem cells. These EVs carry complex assemblies of biologic molecules such as proteins and nucleic acids that can induce a wide variety of effects in recipient cells, including the promotion of regenerative healing, while reducing inflammation and modulating the immune system. Aegle’s EV therapy has the potential to treat a broad range of indications in multiple therapeutic areas, including dermatology, immunology-based diseases, protein deficient disorders and others. For more information about Aegle Therapeutics, please visit www.aegletherapeutics.com.
Company Details
- Employees
- 6
- Address
- Woburn, Ma, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://aegletherapeutics.com/
- Keywords
- Athens.
- HQ
- Woburn, MA
Aegle Therapeutics Questions
Aegle Therapeutics's website is https://aegletherapeutics.com/
Aegle Therapeutics's LinkedIn profile is https://www.linkedin.com/company/aegletherapeutics
Aegle Therapeutics has
6 employees.
View email and phone details for 6
employees at Aegle Therapeutics.
Aegle Therapeutics's industry is
Biotechnology Research
Aegle Therapeutics's top competitors are
Exocobio,
United Therapeutics Corporation,
Coya Therapeutics, Inc.,
Infinimmune,
Ilias Biologics Inc.,
Capricor Therapeutics, Inc.,
Evox Therapeutics Ltd,
Direct Biologics,
Aruna Bio, Inc.,
Exopharm Ltd.
Aegle Therapeutics's categories are Biotechnology Research
